1. Home
  2. OXM vs ANL Comparison

OXM vs ANL Comparison

Compare OXM & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oxford Industries Inc.

OXM

Oxford Industries Inc.

HOLD

Current Price

$40.97

Market Cap

675.3M

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$11.12

Market Cap

611.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OXM
ANL
Founded
1942
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
675.3M
611.1M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
OXM
ANL
Price
$40.97
$11.12
Analyst Decision
Hold
Strong Buy
Analyst Count
4
1
Target Price
$38.00
$20.00
AVG Volume (30 Days)
555.2K
189.5K
Earning Date
06-10-2026
04-10-2026
Dividend Yield
6.80%
N/A
EPS Growth
N/A
N/A
EPS
1.00
N/A
Revenue
$1,477,834,000.00
N/A
Revenue This Year
$2.85
$36.02
Revenue Next Year
$2.63
N/A
P/E Ratio
$38.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.57
$0.88
52 Week High
$51.61
$17.25

Technical Indicators

Market Signals
Indicator
OXM
ANL
Relative Strength Index (RSI) 60.92 53.32
Support Level $40.69 $9.00
Resistance Level $42.12 $12.24
Average True Range (ATR) 1.94 1.41
MACD 0.72 0.07
Stochastic Oscillator 97.51 74.86

Price Performance

Historical Comparison
OXM
ANL

About OXM Oxford Industries Inc.

Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company's business is organized as: Tommy Bahama, Lilly Pulitzer, Johnny Was and Emerging Brands reportable segments. Geographically, the company operates in United States as well as Internationally.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: